Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo
Cart
header search
Search
Skip Nav Destination

On Location

Updates from major medical meetings in the field of hematology/oncology
Clonal Hematopoiesis Associated With Cytopenias After CAR-T Therapy for MM
Katie Robinson
March 12, 2025
Teclistamab Safe for Treating Patients with R/R MM with Renal Impairment
Thomas R. Collins
February 12, 2025
Study of LBCL Confirms Prognostic Value of ctDNA in Second-Line Liso-Cel Versus Standard of Care
Katie Robinson
February 12, 2025
Extramedullary Disease Helps Predict Immune Effector Cell Toxicities After CAR-T in MM
Thomas R. Collins
February 12, 2025
Clonal Hematopoiesis May Prolong Cytopenias After CAR-T Therapy for MM
Katie Robinson
February 11, 2025
CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study
Katie Robinson
February 11, 2025
Physical Function Can Help Gauge ICANS Risk, Study Finds
Thomas R. Collins
February 11, 2025
Non-Viral, Allogeneic BCMA-Directed CAR-T Therapy Eliminates Bridging in R/R MM
Lara C. Pullen, PhD
February 10, 2025
Multimodal Machine Learning Boosts CAR-T Outcome Prediction in LBCL
Thomas R. Collins
February 10, 2025
Cilta-Cel Treatment in Lenalidomide-Refractory MM Results in High Rates of MRD Negativity
Katie Robinson
February 10, 2025
Study Highlights Characteristics of Post-CAR-T Treatment–Related Myeloid Neoplasms
Katie Robinson
February 6, 2025
IL-15 Agonist Boosts Response in Phase II LBCL CAR-T Trial
Thomas R. Collins
February 6, 2025
Predicting Response to Obe-Cel in Patients With R/R B-ALL
Lara C. Pullen, PhD
February 6, 2025
Daratumumab Plus Lenalidomide Shows MRD, PFS Benefit in Newly Diagnosed MM After AHCT in Clinically Relevant Subgroups
Katie Robinson
December 17, 2024
Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab
Lara C. Pullen, PhD
December 13, 2024
Bispecific T-Cell Engager Results in CR, Clears MRD in Patients with R/R Follicular Lymphoma
Anna Azvolinsky, PhD
December 13, 2024
Initial Results Confirm Safety of Lower-Dose Teclistamab as Maintenance in NDMM
Khylia Marshall
December 13, 2024
Teclistamab-Based Induction Regimens Achieve MRD Negativity in Patients With Transplant-Eligible NDMM
Katie Robinson
December 13, 2024
Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma
Lara C. Pullen, PhD
December 13, 2024
Quadruple Combination with Brentuximab Vedotin, Nivolumab Continues to Show Strong Efficacy in Early-Stage cHL
Anna Azvolinsky, PhD
December 10, 2024

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
April 2025

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals